Biblio
Export 1207 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is R [Clear All Filters]
“Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.”, Nat Genet, vol. 45, no. 12, pp. 1452-8, 2013.
, “TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
, “TREM2 variants in Alzheimer's disease.”, N Engl J Med, vol. 368, no. 2, pp. 117-27, 2013.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “C9orf72 nucleotide repeat structures initiate molecular cascades of disease.”, Nature, vol. 507, no. 7491, pp. 195-200, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
, “Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.”, J Am Geriatr Soc, vol. 62, no. 1, pp. 16-24, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.”, J Alzheimers Dis, vol. 48, no. 1, pp. 175-87, 2015.
, “Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.”, J Alzheimers Dis, vol. 48, no. 1, pp. 175-87, 2015.
, “Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.”, J Alzheimers Dis, vol. 48, no. 1, pp. 175-87, 2015.
, “Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.”, J Alzheimers Dis, vol. 48, no. 1, pp. 175-87, 2015.
, “Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.”, J Alzheimers Dis, vol. 48, no. 1, pp. 175-87, 2015.
, “Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.”, J Alzheimers Dis, 2015.
, “Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus.”, J Alzheimers Dis, 2015.
, , ,